ScienceHealth & FitnessMedicineEducation

Hematologic Oncology Update

Dr. Neil Love

Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.

Play

Open in

25 episodes
Avg 1 hr 2 min
English

Episodes 25

Newest Oldest Longest

All5 Unplayed5 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

S25 · E75
April 20 · 58 min
Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
Dr Amir Fathi from Massachusetts General Hospital in Boston, Massachusetts, and Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discuss key clinical trial data surrounding the use of menin inhibitors in the management of AML. CME information and select publications here.
S25 · E74
April 10 · 24 min
CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma. CME information and select publications here.
S25 · E73
April 1 · 24 min
Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia. CME information and select publications here.
S25 · E72
March 23 · 24 min
CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson
Dr Paul G Richardson from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses how CELMoDs function, available data with these agents and their possible future role in the treatment of multiple myeloma. CME information and select publications here.
S25 · E71
March 21 · 29 min
Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review
Dr Hanny Al-Samkari from Massachusetts General Hospital in Boston discusses recent developments from the ASH 2025 Annual Meeting involving the use of Bruton tyrosine kinase inhibitors and BAFF-R antagonists in the treatment of immune thrombocytopenia. CME information and select publications here.

Showing 21–25 of 25 episodes

Hematologic Oncology Update

Episodes 25

Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances

CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson

Immune Thrombocytopenia — Microlearning Activity 4 with Dr Hanny Al-Samkari: ASH 2025 Review

CELMoDs for Multiple Myeloma — Microlearning Activity 1 with Dr Paul G Richardson

Immune Thrombocytopenia — Microlearning Activity 3 with Dr Hanny Al-Samkari: ASH 2025 Review